A KAIST research team has developed an RNA-based therapeutic strategy that blocks a brain signal to prevent muscle loss and extend survival in cancer patients. The treatment showed significant improvements in both muscle loss and metabolic dysfunction, with a notable increase in survival rates among treated mice.
A study found that reshaping the gut microbiome with antibiotics can significantly reduce liver clearance and double chemotherapy delivery to tumors. This approach has potential as a strategy to enhance nanoparticle-based cancer drugs.
A multidisciplinary team of Penn researchers has developed a platform that delivers a combination of cancer-fighting therapies to treat oral squamous cell carcinoma. The findings show that the platform significantly reduces tumor burden and extends survival in aggressive, p53-therapy-resistant cancer models.
A recent analysis found that while genomic testing increased among Medicare recipients, many patients still lack next-generation sequencing tests. This limits their access to precision medicine and targeted therapies. The study highlights the need for further research on how increased testing impacts patient outcomes.
Researchers found that immature NK cells in donated cord blood can undermine CAR NK cell therapy by creating false targets for therapeutic cells to attack. Removing these cells before manufacturing improves therapy outcomes, persistence and antitumor activity in preclinical models of lymphoma and ovarian cancer.
Researchers discovered a signaling pathway activated by acidic tumor environments that drives resistance to PARP inhibitors. Blocking the pathway resensitizes tumors, suggesting a potential new therapeutic strategy for overcoming acquired resistance.
Circulating circRNAs show high cell-type and tissue specificity, making them ideal for non-invasive cancer management. They can be detected in multiple body fluids and reflect treatment response, positioning them as functional drivers of therapy resistance.
The University of Tennessee has appointed Carolyn J. Anderson as a UT-Oak Ridge National Laboratory Governor's Chair for Nuclear Medicine. She will focus on researching radioisotopes produced at ORNL for targeted alpha-emitting radiotherapy, which can precisely kill cancer cells with minimal side effects.
Dr. Yi Li receives CPRIT funding to develop treatments for solitary fibrous tumor, a rare cancer driven by gene fusions. Researchers are working on novel therapies, including immunotherapy and antisense oligonucleotides, to reduce cancer-causing signal activity.
A new study published in eBioMedicine shows that combining irinotecan with standard chemoradiotherapy improves survival against advanced rectal cancer, particularly in those with high concentrations of cancerous cells. The AI-powered analysis revealed a 43% reduction in cancer recurrence and a 50% reduction in death risk.
Researchers discover how tumors hijack the thymus to evade immune surveillance by transporting tumor antigens there. Disrupting a specific chemokine receptor may enhance anti-tumor immunity and improve cancer treatment outcomes.
Researchers at Nagoya University discovered that complement C3 protein acts inside tumors to prevent immunosuppressive cells, improving cancer immunotherapy effectiveness. Higher levels of C3 in tumor tissue were associated with better treatment outcomes and survival rates in patients.
A comprehensive, sustained approach to treating tobacco dependence in patients undergoing cancer treatment has been shown to double quit rates compared to referral to a Quitline alone. The study found that 81% of participants who received virtual sustained treatment attended counseling sessions and had higher medication use rates.
Researchers discovered 171 distinct mutations causing MET exon 14 skipping in lung cancer patients. RNA-based testing confirmed these alterations, highlighting the importance of complementary diagnostic approaches.
SourceElsevier·JournalJournal of Molecular Diagnostics·TypeData/statistical analysis·DateJul 23, 2026
Researchers analyzed over 600 tumors from 544 patients and found distinct genomic signatures of DNA changes linked to different chemotherapies. These patterns appeared as early as 91 days after treatment began, allowing clinicians to track treatment-resistant tumours and potentially reduce toxic effects. The study could lead to a more ...
Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk of recurrence after surgery. Nearly 80% of patients who received this treatment remained free of disease progression, recurrence, or death two years after treatment began.
Researchers used advanced 3D genome mapping technology to study prostate cancer cells and discovered a new feature of gene control networks that could help fight cancer. The study found that enhancers work cooperatively in 3D networks, with some acting as central hubs that control many genes.
A research team has overcome two major hurdles for photo thermal therapy, a less invasive treatment option than surgery and radiation. They created a new biodegradable protein called IDP1 that helps nanoparticles avoid immune detection, and developed an ultra-thin endoscope to deliver laser light directly into tumors.
A UMass Amherst-led team is developing a new approach to prevent bladder cancer recurrence by exfoliating the bladder lining. The technology uses irreversible electroporation to target premalignant cells, offering a potential alternative to surgical removal or aggressive treatments.
Researchers found that a new treatment regimen can slow cancer progression in patients with functional high-risk (FHR) multiple myeloma. The study defines FHR multiple myeloma as progressing within 36 months of starting treatment, indicating a survival prognosis of less than 2 years after progression.
The grant supports the development of therapies with fewer side effects for triple-negative breast cancer, a highly aggressive and difficult-to-treat form of breast cancer. The researchers aim to target UBR5 protein, which is overproduced in aggressive breast cancers and several other malignancies.
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
Researchers at Johns Hopkins Medicine have found a potential therapeutic target that can improve the potency of decitabine, a chemotherapy commonly used to treat bone marrow disorders and acute myeloid leukemia. By blocking DCTPP1's function with newly identified inhibitors, cancer cells become more susceptible to decitabine's ability ...
The ECOG-ACRIN ENDURANCE trial found that indefinite lenalidomide maintenance had no survival benefit and more toxicity compared to stopping treatment after 2 years in patients not undergoing a stem cell transplant. The study suggests that fixed duration treatment can significantly reduce healthcare costs.
A new study found that a virtual smoking cessation treatment program nearly doubled quit rates for cancer patients who currently smoke. The program, delivered at community oncology care settings, was both cost-effective and satisfying for patients. Participants who completed more sessions had a higher likelihood of quitting.
Researchers developed nanoparticles that retain their protective coating in normal tissue but shed it upon reaching tumor tissue, releasing anticancer drugs. This technology reduces systemic side effects and enhances treatment efficacy.
A novel therapy targeting the bone marrow microenvironment is shown to accelerate recovery and promote hematopoietic regeneration after injury. Pharmacological activation of YAP/TAZ improves BM niche recovery, enhancing engraftment and white blood cell recovery following HSCT.
A nationwide analysis found that many radiation oncology clinics have closed, particularly in rural communities, reducing access to lifesaving cancer treatment. The study suggests that understanding which communities are most vulnerable can help policymakers develop strategies to preserve access.
A new study found that over 50 million Americans live in counties without a radiation oncology clinic, highlighting vulnerabilities in the nation's cancer care infrastructure. Radiation oncology practices have closed disproportionately in rural areas and freestanding settings, raising concerns about patients' access to cancer care.
A new strategy makes stem cell transplants safer by replacing chemotherapy-based treatment with targeted antibodies that recognize specific markers on blood-forming stem cells. This approach allows for less toxic treatment and could enable chemotherapy-free or chemotherapy-sparing transplantation approaches.
Researchers at Umeå University have developed a new antibody that successfully halted tumor growth and metastasis in aggressive prostate cancer. The treatment works through a novel mechanism of action, potentially reducing side effects.
Researchers identified why some patients with rare blastic plasmacytoid dendritic cell neoplasm (BPDCN) leukemia don't respond to tagraxofusp. Severe TET2 gene mutations and low TXNRD1 enzyme levels contribute to resistance, suggesting these biomarkers could predict treatment outcomes.
Physicists at UTEP have discovered a new type of manganese ferrite nanoparticle that can deliver targeted heat treatment to tumors, potentially improving cancer therapies. The nanoparticles were found to produce a stronger heating response than other materials, making them a promising building block for future treatments.
Researchers have developed a gene-editing tool that unlocks the secrets of fungi, a kingdom rich in antibacterial compounds. The tool, called fPE7max, enables precise control over DNA sequences and has identified three novel molecules with anti-cancer properties.
A Phase I/II study showed high tumor shrinkage and substantial reductions in cancer DNA detected in the bloodstream. The treatment combination of zoldonrasib with chemotherapy improved patient outcomes, suggesting a potential breakthrough in personalized treatment for pancreatic cancer.
Researchers at the University of Warwick and Monash University have uncovered a molecular basis for combinatorial biosynthesis, a strategy to create multiple versions of powerful cancer therapies. By understanding how bacterial enzymes interact, they can design new therapies with improved potency and selectivity.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
The collaboration aims to eliminate barriers to screening and access for medically underserved women, leveraging data science and community-based research to develop targeted solutions. By listening to residents' experiences and challenges, USC and Novartis will create lasting improvements in breast cancer care.
Researchers at Rutgers University used simulation to identify bottlenecks in their blood cancer clinic and implemented changes that reduced visit times from 90 minutes to less than 30 minutes. The approach could be applied to other medical oncology offices, improving efficiency and patient care.
Researchers have identified immune markers that can help doctors determine which breast cancer patients are unlikely to benefit from chemotherapy. The new AI-based method analyzes the body's own immune cells found near a tumor, providing additional insight to identify patients who can safely have chemotherapy withheld.
Researchers develop AI framework using principles of superposition and entanglement to tailor cancer treatment to patients' entire molecular background. The technique predicts health outcomes and suggests genes to target, outperforming standard biomarkers in clinical trials.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
A target trial emulation study found that delaying treatment of moderate pre-cancerous cervical cells (CIN 2) does not increase three-year cancer risk and reduces unnecessary excisions. The study suggests it may be safe to delay treatment, especially for lower-risk CIN 2, by adopting careful follow-up strategies.
A meta-analysis of studies found that guideline-recommended heart failure therapies protect heart function in patients treated for cancer. RAAS inhibitors and beta-blockers improved left ventricular ejection fraction, while mineralocorticoid antagonists showed encouraging protective effects.
Researchers at UT MD Anderson Cancer Center have achieved high response rates in patients with hard-to-treat acute myeloid leukemia (AML) using an all-oral combination therapy. The study also provides insights into the origins of cancer, revealing that tumors evolve rapidly through bursts of genetic changes.
St. Jude Children's Research Hospital has been recognized by the World Health Organization (WHO) as a Collaborating Centre for Childhood Cancer. The redesignation aims to improve global pediatric cancer outcomes and expand access to quality care for children worldwide.
Researchers found that radiation therapy not only targets tumor cells but also activates immune pathways to make tumors more receptive to immunotherapy. The study suggests that radiation-immunotherapy combination strategies could improve patient outcomes by reshaping the surrounding immune landscape and recruiting T cells.
The AI model ARTIMES measures tumor volume rather than diameter, allowing for more accurate predictions of patient survival. This enables physicians to make informed decisions about treatment, potentially leading to improved patient outcomes and reduced healthcare costs.
Researchers at Purdue University have developed a next-generation technology platform designed to dramatically accelerate one of the slowest stages of cancer drug discovery. The platform combines chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow, allowing researchers to generate, evaluate, ...
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the selection of five early-career scientists to pursue four-year grants in cancer research. The scholars will investigate big questions about cancer development, diagnosis, and treatment.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
A two-year fixed-duration triplet therapy of pirtobrutinib, venetoclax, and rituximab improves progression free survival for patients with relapsed/refractory CLL compared to standard therapy. Peripheral blood undetectable minimal residual disease rates are higher in patients receiving the triplet therapy.
Researchers developed DNA tetrahedrons with Vitamin E-derived molecules for targeted cancer treatment, enhancing cellular uptake and improving anticancer efficacy. The modification triggered oxidative stress in cancer cells, leading to programmed cell death.
Researchers at UC Irvine have discovered a mechanism that combines DNA damage and inflammatory signaling in tumor cells, potentially improving cancer treatment response. The study found that a combination of PARP inhibitors and TOP1 blockers triggers an 'alarm signal' inside cancer cells, alerting the immune system to eliminate them.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Rice University has received a $2 million CPRIT award to advance cancer research, including new studies in immunotherapy and ovarian cancer. The funding will support the expansion of the Genetic Design and Engineering Center, which provides a centralized hub for DNA tools used in cancer research.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.